• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于 siRNA 递送的靶向抗体-聚合物缀合物。

Site-specific antibody-polymer conjugates for siRNA delivery.

机构信息

Department of Chemistry, The Scripps Research Institute , La Jolla, California 92037, United States.

出版信息

J Am Chem Soc. 2013 Sep 18;135(37):13885-91. doi: 10.1021/ja4059525. Epub 2013 Sep 5.

DOI:10.1021/ja4059525
PMID:23924037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3955097/
Abstract

We describe here the development of site-specific antibody-polymer conjugates (APCs) for the selective delivery of small interference RNAs (siRNAs) to target cells. APCs were synthesized in good yields by conjugating an aminooxy-derivatized cationic block copolymer to an anti-HER2 Fab or full-length IgG by means of genetically encoded p-acetyl phenylalanine (pAcF). The APCs all showed binding affinity comparable to that of HER2 as their native counterparts and no significant cellular cytotoxicity. Mutant S202-pAcF Fab and Q389-pAcF IgG polymer conjugates specifically delivered siRNAs to HER2(+) cells and mediated potent gene silencing at both the mRNA and protein levels. However, a mutant A121-pAcF IgG polymer conjugate, despite its high binding affinity to HER2 antigen, did not induce a significant RNA interference response in HER2(+) cells, presumably due to steric interference with antigen binding and internalization. These results highlight the importance of conjugation site on the activity of antibody-polymer-based therapeutics and suggest that such chemically defined APCs may afford a useful targeted delivery platform for siRNAs or other nucleic acid-based therapies.

摘要

我们在这里描述了用于将小干扰 RNA(siRNA)选择性递送至靶细胞的靶向抗体-聚合物缀合物(APC)的开发。通过用遗传编码的对乙酰基苯丙氨酸(pAcF)将氨氧基衍生的阳离子嵌段共聚物缀合到抗 HER2 Fab 或全长 IgG 上来,以良好的产率合成了 APC。所有 APC 均表现出与天然抗体相当的结合亲和力,且没有明显的细胞毒性。突变体 S202-pAcF Fab 和 Q389-pAcF IgG 聚合物缀合物可特异性地将 siRNA 递送至 HER2(+)细胞,并在 mRNA 和蛋白质水平上均介导有效的基因沉默。然而,尽管突变体 A121-pAcF IgG 聚合物缀合物对 HER2 抗原具有高结合亲和力,但并未在 HER2(+)细胞中引起明显的 RNA 干扰反应,这可能是由于与抗原结合和内化的空间位阻干扰所致。这些结果强调了抗体-聚合物基治疗剂缀合部位对其活性的重要性,并表明这种化学定义的 APC 可能为 siRNA 或其他核酸基治疗提供有用的靶向递药平台。

相似文献

1
Site-specific antibody-polymer conjugates for siRNA delivery.用于 siRNA 递送的靶向抗体-聚合物缀合物。
J Am Chem Soc. 2013 Sep 18;135(37):13885-91. doi: 10.1021/ja4059525. Epub 2013 Sep 5.
2
Biotinylated polyacrylamide-based metal-chelating polymers and their influence on antigen recognition following conjugation to a trastuzumab Fab fragment.基于生物素化聚丙稀酰胺的金属螯合聚合物及其在与曲妥珠单抗 Fab 片段缀合后对抗原识别的影响。
Biomacromolecules. 2012 Sep 10;13(9):2831-42. doi: 10.1021/bm300843u. Epub 2012 Aug 7.
3
A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.一种与MMAE偶联的新型人源化抗HER2抗体具有强大的抗肿瘤活性。
Breast Cancer Res Treat. 2015 Aug;153(1):123-33. doi: 10.1007/s10549-015-3503-3. Epub 2015 Aug 8.
4
Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.来自合成抗体文库的针对 HER2 靶点的抗体药物偶联物在人源 HER2 阳性胃癌异种移植模型中具有很强的抗肿瘤活性。
MAbs. 2019 Jan;11(1):153-165. doi: 10.1080/19420862.2018.1541370. Epub 2018 Nov 8.
5
Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.曲妥珠单抗单甲基澳瑞他汀 E 偶联物在体外对人 HER2 阳性乳腺癌表现出强大的细胞毒性活性。
J Cell Physiol. 2019 Mar;234(3):2693-2704. doi: 10.1002/jcp.27085. Epub 2018 Sep 24.
6
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.抗肥胖药物奥利司他(赛尼可TM)对乳腺癌细胞的抗肿瘤作用:阻断细胞周期进程、促进凋亡性细胞死亡以及PEA3介导的Her2/neu(erbB-2)癌基因转录抑制。
Ann Oncol. 2005 Aug;16(8):1253-67. doi: 10.1093/annonc/mdi239. Epub 2005 May 3.
7
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).曲妥珠单抗衍生药物德曲妥珠单抗(DS-8201a)和(Vic-)曲妥珠单抗杜卡鲁单抗(SYD985):新型抗 HER2 抗体药物偶联物在乳腺癌中的应用,超越 T-DM1
Eur J Med Chem. 2019 Dec 1;183:111682. doi: 10.1016/j.ejmech.2019.111682. Epub 2019 Sep 6.
8
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.双特异性抗体和抗体药物偶联物(ADCs)桥接 HER2 和催乳素受体可提高 HER2 ADC 的疗效。
Mol Cancer Ther. 2017 Apr;16(4):681-693. doi: 10.1158/1535-7163.MCT-16-0658. Epub 2017 Jan 20.
9
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.设计优化和 Her2/neu 靶向免疫毒素的表征:体外和体内比较疗效研究。
Oncogene. 2014 Jan 23;33(4):429-39. doi: 10.1038/onc.2012.612. Epub 2013 Feb 4.
10
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.一种通过化学选择性双点击策略实现基于抗体的治疗药物的即插即用方法。
Nat Commun. 2015 Mar 31;6:6645. doi: 10.1038/ncomms7645.

引用本文的文献

1
Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment.利用聚合物药物偶联物推进核酸递送与治疗的治疗策略
Int J Nanomedicine. 2025 Jan 4;20:25-52. doi: 10.2147/IJN.S429279. eCollection 2025.
2
Biosynthesis of Halogenated Tryptophans for Protein Engineering Using Genetic Code Expansion.利用遗传密码扩展进行蛋白质工程的卤代色氨酸生物合成。
Chembiochem. 2024 Oct 16;25(20):e202400366. doi: 10.1002/cbic.202400366. Epub 2024 Sep 3.
3
Applications of genetic code expansion technology in eukaryotes.遗传密码扩展技术在真核生物中的应用。
Protein Cell. 2024 May 7;15(5):331-363. doi: 10.1093/procel/pwad051.
4
Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins.靶向抗体药物偶联物:超越细胞毒素的Payload 研究
Molecules. 2023 Jan 17;28(3):917. doi: 10.3390/molecules28030917.
5
Biopolymer-Based Nanosystems for siRNA Drug Delivery to Solid Tumors including Breast Cancer.用于将siRNA药物递送至包括乳腺癌在内的实体瘤的基于生物聚合物的纳米系统。
Pharmaceutics. 2023 Jan 1;15(1):153. doi: 10.3390/pharmaceutics15010153.
6
Preparation of Temperature-Responsive Antibody-Nanoparticles by RAFT-Mediated Grafting from Polymerization.通过可逆加成-断裂链转移(RAFT)介导的从聚合反应制备温度响应性抗体纳米颗粒。
Polymers (Basel). 2022 Oct 28;14(21):4584. doi: 10.3390/polym14214584.
7
Manipulating Cell Fates with Protein Conjugates.利用蛋白缀合物改变细胞命运。
Bioconjug Chem. 2022 Oct 19;33(10):1771-1784. doi: 10.1021/acs.bioconjchem.2c00226. Epub 2022 Aug 15.
8
Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates.抗体 - 寡核苷酸偶联物:抗体 - 药物偶联物的新变化
J Clin Med. 2021 Feb 18;10(4):838. doi: 10.3390/jcm10040838.
9
miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome.微小RNA-21、中介体与心肾综合征中的潜在治疗靶点
Front Pharmacol. 2020 May 15;11:726. doi: 10.3389/fphar.2020.00726. eCollection 2020.
10
Generation and validation of structurally defined antibody-siRNA conjugates.生成和验证结构定义的抗体-siRNA 缀合物。
Nucleic Acids Res. 2020 Jun 4;48(10):5281-5293. doi: 10.1093/nar/gkaa286.

本文引用的文献

1
Defined Folate-PEG-siRNA Conjugates for Receptor-specific Gene Silencing.定义的叶酸-PEG-siRNA 缀合物用于受体特异性基因沉默。
Mol Ther Nucleic Acids. 2012 Jan 31;1(1):e7. doi: 10.1038/mtna.2011.10.
2
Self-assembled antibody multimers through peptide nucleic acid conjugation.通过肽核酸连接自组装抗体多聚体。
J Am Chem Soc. 2013 Jan 9;135(1):340-6. doi: 10.1021/ja309505c. Epub 2012 Dec 21.
3
Antibody-linked spherical nucleic acids for cellular targeting.抗体连接的球形核酸用于细胞靶向。
J Am Chem Soc. 2012 Oct 10;134(40):16488-91. doi: 10.1021/ja306854d. Epub 2012 Sep 28.
4
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.利用非天然氨基酸合成定点抗体药物偶联物。
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16101-6. doi: 10.1073/pnas.1211023109. Epub 2012 Sep 17.
5
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.单链 RNA 通过 RNAi 强效且等位基因选择性地抑制突变型亨廷顿蛋白的表达。
Cell. 2012 Aug 31;150(5):895-908. doi: 10.1016/j.cell.2012.08.002.
6
Single-stranded siRNAs activate RNAi in animals.单链 siRNAs 在动物中激活 RNAi。
Cell. 2012 Aug 31;150(5):883-94. doi: 10.1016/j.cell.2012.08.014.
7
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery.分子自组装核酸纳米颗粒用于靶向体内 siRNA 递送。
Nat Nanotechnol. 2012 Jun 3;7(6):389-93. doi: 10.1038/nnano.2012.73.
8
Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.使用遗传编码的非天然氨基酸合成双特异性抗体。
J Am Chem Soc. 2012 Jun 20;134(24):9918-21. doi: 10.1021/ja303904e. Epub 2012 Jun 6.
9
T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles.利用抗体偶联壳聚糖纳米粒递送 T 细胞特异性 siRNA。
Bioconjug Chem. 2012 Jun 20;23(6):1174-80. doi: 10.1021/bc2006219. Epub 2012 May 31.
10
Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.靶向递送 PLK1-siRNA 的 ScFv 抑制 Her2+乳腺癌的生长和转移。
Sci Transl Med. 2012 Apr 18;4(130):130ra48. doi: 10.1126/scitranslmed.3003601.